Australian first for ENVISION study

Recently, the first participant in Australia was successfully screened for the ENVISION study at the Australian Alzheimer’s Research Foundation.


The Phase 3b/4 Biogen ENVISION study is testing the drug Aduhelm (aka Aducanumab), which is a new and exciting treatment for mild cases of Alzheimer’s disease.

Paula Mather, from AARF’s Clinical Trial Division, said, “We are proud and excited to be taking part in this study and having the opportunity to provide access to ADUHELM to participants with Alzheimer’s disease in Western Australia.”

Ms Mather said more participants were needed for the study.

Aducanumab was the first therapy to demonstrate that removing beta-amyloid (one of the hallmarks of Alzheimer’s disease) from the brain reduces cognitive and functional decline in people living with early Alzheimer’s.


Fast tracked

The drug was given fast-tracked approval by the U.S. Food and Drug Administration (FDA), because of the critical need for a treatment for Alzheimer’s disease.

As part of the FDA approval process, the pharmaceutical company behind the drug, Biogen, is required to run studies to verify the clinical benefits of the drug. It is hoped the data will support the full approval of Adulhelm to the general population.

The Australian Alzheimer’s Research Foundation is proud and excited to be taking part in this study and to have the opportunity to provide access to Aduhelm to participants with early stages of Alzheimer’s disease in WA.


If you would like to take part in the study, are aged 60 – 85 years, and have MCI (mild cognitive impairment) or mild Alzheimer’s disease please contact Paula Mather, Clinical Trial Coordinator on (08) 9389 6433 or email

You can register your interest in participating in the ENVISION Study here